Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 7/20 | 0.65 |
| ▸ | GCK | P35557 | 7/20 | 0.38 |
| ▸ | GCKR | Q14397 | 7/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480232 | 1.00 | ALOX5AP (0.65) | ALOX5APGCKGCKRTLR9TLR8 | |
| SCHEMBL480220 | 0.91 | ALOX5AP (0.80) | ALOX5APGCKGCKRSYKJAK2 | |
| SCHEMBL480102 | 0.91 | ALOX5AP (0.80) | ALOX5APGCKGCKRSYKJAK2 | |
| SCHEMBL2990063 | 0.86 | ALOX5AP (0.52) | ALOX5APGCKGCKRTLR9TLR8 | |
| SCHEMBL3001060 | 0.85 | ALOX5AP (0.64) | ALOX5APGCKGCKRTLR9TLR8 | |
| SCHEMBL13262239 | 0.84 | ALOX5AP (0.60) | ALOX5APGCKGCKRTLR9TLR8 | |
| SCHEMBL13230255 | 0.81 | ALOX5AP (0.57) | ALOX5APGCKGCKRFEN1 | |
| SCHEMBL480242 | 0.80 | ALOX5AP (0.74) | ALOX5APGCKGCKR | |
| SCHEMBL480253 | 0.80 | ALOX5AP (0.74) | ALOX5APGCKGCKR | |
| SCHEMBL480259 | 0.79 | ALOX5AP (1.00) | ALOX5APGCKGCKRSYKFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2064204-B1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK SHARP & DOHME (US) | 2012-02-01 | — | — | EP | claimed |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | claimed |
| EP-2064204-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008030369-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | claimed |
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2064204-B1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK SHARP & DOHME (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-2064204-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | Merck & Co., Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008030369-A1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | ALOX5AP 14/4885GCK 2115/4885GCKR 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.